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SUMMARY
We performed a systematic review to estimate the eﬀectiveness of vaccination, in addition to
chemoprophylaxis, in preventing meningococcal disease among household contacts. Medline,
EMBASE, EMGM, and EUIBIS were used for data collection. Studies reporting on at least 100
primary cases and on subsequent cases in household settings with follow-up of more than 2 weeks
after onset of disease in the primary case were reviewed. A meta-analysis was used to calculate
the average attack rate in household contacts given chemoprophylaxis 14–365 days after onset of
disease in the primary case. In total, 652 studies were identiﬁed, ﬁve studies and one unpublished
report met the inclusion criteria. The weighted average attack rate was 1.1/1000 household
contacts (95% CI 0.7–1.7). This review supports vaccination of household contacts in addition to
chemoprophylaxis to reduce the risk of meningococcal disease among household contacts of a
case caused by a vaccine-preventable serogroup.
INTRODUCTION
Meningococcal disease is a severe illness with high case
fatality (5–10%) and frequent sequelae (10–20%)
that require lifelong medical attention [1–3]. Long-
term complications include headaches, skin scarring,
limb amputation, deafness and learning diﬃculties.
One well-deﬁned risk factor for developing meningo-
coccal disease is being a close contact of a primary
case [4, 5]. Treatment with rifampicin, ceftriaxone,
or ciproﬂoxacin is eﬀective in the eradication of me-
ningococcal carriage and reduces the number of sub-
sequent cases in a household setting [6, 7]. However,
subsequent cases still occur, and it has been suggested
that chemoprophylaxis merely postpones the onset of
disease in household members [8]. Some countries also
recommend chemoprophylaxis for the primary case
before discharge from hospital. Even so, eradication
of carriage within households using chemoprophyl-
axis cannot be expected to eliminate the short-term
risk of meningococcal disease among household mem-
bers. Appropriate immunization of close contacts
could add medium and longer term protection.
Two types of vaccines are currently licensed in
Europe; polysaccharide vaccines against serogroups
A, C, W135 and Y and newer protein-polysaccharide
conjugate vaccines against serogroup C. A survey in
2007 found that 14 European countries recommended
vaccination of household contacts in addition to
chemoprophylaxis, and seven did not [9]. The lack of
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evidence for eﬀectiveness of strategies used in public
healthmanagement ofmeningococcal disease is a well-
recognized obstacle in the development of coherent
policies and is reﬂected in the variations in approach
[10].We systematically reviewed the risk of subsequent
cases among household contacts who had already
received eﬀective chemoprophylaxis (rifampicin, cip-
roﬂoxacin, ceftriaxone) after diagnosis of meningo-
coccal disease in the primary case.
METHODS
Systematic literature review
We identiﬁed studies by searching Medline (1 January
1966 to 31 March 2006) and EMBASE (1 January
1974 to 31 March 2006) and by examining the refer-
ences of the papers that met the inclusion criteria.
We used the following search terms:Neisseriameningi-
tidis ormeningococcal disease and subsequent cases or
associated cases or household contacts or chemopro-
phylaxis or subsequent attack rate or secondary at-
tack rate or close contacts. In addition, members of
the European Monitoring Group for Meningococci
(www.emgm.eu) and members of the European Union
Invasive Bacterial Infection Surveillance network
(www.euibis.org) were contacted and asked to inform
us of any relevant published or unpublished data.
Inclusion and exclusion criteria
Abstracts were reviewed by M.H., and initially selec-
ted on title and abstract alone. The remaining papers
were reviewed by M.H. and J.S., and further selected
based upon the full text. Studies reporting on at least
100 sporadic cases and on subsequent cases in house-
hold contacts after eﬀective chemoprophylaxis with a
follow-up period of more than 2 weeks after onset of
disease in the index case were included in the meta-
analysis. Eﬀective chemoprophylaxis was taken to be
a short course of rifampicin, or one dose of ceftriax-
one or ciproﬂoxacin [7]. Papers reporting speciﬁcally
on outbreaks were excluded to avoid bias from un-
usually high attack rates.
Case deﬁnitions
A primary case was deﬁned as the ﬁrst case of invasive
disease due to N. meningitidis in a household setting.
A household contact was deﬁned as any person living
in the same house or sharing the same sleeping
quarters as the primary case in the 10 days prior to the
onset of disease in the index case. A subsequent case
of potentially vaccine-preventable disease was deﬁned
as a case of N. meningitidis in a household contact
14–365 days after onset of disease in the primary case.
Assumptions
The minimum interval of 14 days was the sum of the
period between onset of meningococcal disease in the
primary case and vaccination of household contacts
(estimate 7 days) and the period between vaccination
and development of immunity (estimate 7 days).
Where data on some variables was incomplete, e.g.
size of households in primary cases, proportion of
contacts given prophylaxis, we made an estimate
based on data from similar settings in other studies.
In one paper [11] where only aggregated data on times
of subsequent cases was available, we assumed an
equal time distribution of subsequent cases within
each given time period. Vaccine eﬃcacy of 85–95%
and case fatality of 5–10% were used in the meta-
analysis [1, 12, 13].
Analysis
The attack rates in household contacts in the included
studies were tested for heterogeneity using a Cochran
Q test. A Poisson model was used to calculate the
weighted average attack rate in the meta-analysis
using Stata 9.2 software (Stata Corporation, College
Station, TX, USA). The number of household con-
tacts needed to vaccinate to prevent one case of
vaccine-preventable meningococcal disease among
household contacts given chemoprophylaxis was cal-
culated using the following formula:
(1000=attack rate per 1000 household contacts)
vaccine efficacy
:
Similarly, the formula for the number to prevent one
death was:
1000
.
attack rate per 1000
household contacts
vaccine efficacy
0
@
1
A,case fatality:
We undertook a sensitivity analysis on these esti-
mates.
RESULTS
The literature search identiﬁed 652 abstracts, of which
173 were duplicates. After review of the abstracts 447
1442 M. R. Hoek and others
were excluded. After review of the full text of 32
papers by two authors, six were included in the meta-
analysis [11, 14–18] (Fig. 1). The main reasons for
exclusion were reports of small outbreaks (<10
cases), reports on cases outside the household setting,
or administration of ineﬀective chemoprophylaxis
to contacts.
All were observational studies that measured attack
rates in household contacts of primary cases. Three
studies were prospective (data collected as clusters
occurred) and three retrospective. We found no
randomized controlled trials or observational studies
that compared attack rates in vaccinated and un-
vaccinated groups after chemoprophylaxis. The six
studies reported on a total of 4630 primary cases
and 30 household clusters with 40 subsequent cases
(Table 1).
Meningococcal disease attack rates among
household contacts (those receiving eﬀective chemo-
prophylaxis) in the six studies were statistically homo-
geneous (Q=1.469, P=0.689). Therefore a ﬁxed-
eﬀect Poisson model was used for the meta-analysis.
The attack rate derived from this model was 1.08/
1000 contacts (95% CI 0.7–1.7) (Table 2) in the time
period 14–365 days after disease onset in the primary
case. After a case of meningococcal disease due to a
vaccine-preventable serogroup, our best estimate of
the number of household contacts needing vaccination
(in addition to chemoprophylaxis) to prevent one case
ranged between 638 and 1678.
Duration of follow-up was at least 31 days in all
studies. Two studies had no follow-up beyond 31 days
[15, 17] and the end point was not well deﬁned in three
studies [11, 16, 18]. In one study [11] the time interval
between the primary and the subsequent case was re-
ported as aggregated data (individual cluster data not
available from authors) without precise dates of sub-
sequent cases among household contacts. No studies
reported on subsequent cases beyond a 1-year period.
In one study [14] 93% of contacts in household
clusters had received chemoprophylaxis. In another
study [11], covering an earlier period in the same
country, no information was available on this pro-
portion. For analysis we assumed that 95% of
household contacts of primary cases were given
eﬀective chemoprophylaxis in both these studies.
Proportions of contacts given eﬀective prophylaxis in
the other studies varied between 25% and 90%
(Table 1).
All studies included laboratory-conﬁrmed and clini-
cally diagnosed cases. Of the clusters in households
given chemoprophylaxis, all the cases in household
contacts were microbiologically conﬁrmed in three
studies [11, 16, 18] and none had a diﬀerent serogroup
to that of the primary case. In two studies there were
no cases in these contacts [15, 17], and in one study
[14] it was reported that 67% of cases in clusters were
conﬁrmed and that cases within all household clusters
were caused by the same or possibly the same sero-
group.
DISCUSSION
Meningococcal disease is a severe illness with high
attack rates in household contacts. Our best estimate
of the attack rate among household contacts who re-
ceived chemoprophylaxis with an antibiotic capable
of eradicating meningococcal carriage (108/100 000)
was 11 times higher than the CDC threshold for mass
vaccination in outbreaks (10/100 000) [18]. Using
existing data on vaccine eﬃcacy, we estimated that
between 640 and 1680 contacts need vaccinating to
prevent a case. This is less or similar to equivalent
ﬁgures in vaccination programmes that have been
implemented in developed countries and that are
considered cost eﬀective, such as seasonal inﬂuenza
and routine pneumococcal immunization [20, 21].
Cost-eﬀectiveness of ameningococcal vaccination pol-
icy for contacts would depend on the costs of vacci-
nation and the health-care costs of case management,
both varying by type of vaccine used (conjugate or
Potentially relevant papers
identified through literature search
(n = 652)
Duplicate papers removed (n = 173)
Deduplicated potentially relevant
papers identified through literature
search (n = 479)
After reviewing abstracts, papers
excluded with reasons (n = 447)
Potentially relevant papers - full text
obtained (n = 32)
After reviewing full text, papers
excluded with reasons (n = 26)
Papers with useable information for
inclusion in meta-analysis (n = 6)
Fig. 1. Progress through the stages of the literature review.
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Table 1. Characteristics of studies investigating subsequent cases of meningococcal disease in household contacts used in this review
Paper Hastings, 1997 [14] Sholten, 1993 [16] Samuelsson,
2000 [17]
Cooke, 1989 [11] CDC, 1976 [15] Stefanoﬀ, 2008 [18]
Country England and Wales Netherlands Denmark England and Wales USA Poland
Study period 1 Jan. 1993–
31 Mar. 1995
1 Apr. 1989–
30 Apr. 1990
(but not July–
Sept. 1989)
20 Oct. 1995–
30 Apr. 1997
1 Jan. 1984–31
Dec. 1987
Nov. 1973–
Mar. 1974 & Jan.
1975–Apr. 1975
1 Jan. 2003–31 Dec.
2006
Follow-up period after the primary case in days 365 days >1 month 31 days >1 month 31 days >1 month
Study design: all observational Retrospective Prospective Prospective Retrospective Prospective Retrospective
Case deﬁnition Clinically diagnosed and/or laboratory conﬁrmed
Total number of primary cases 2809 502 172 3239 512 635
Number of clusters 11 7 2 16 5 5
Total number of subsequent cases 20 7 2 17 6 5
Serogroup of clusters B, 70%; C,
30% of clusters
B, 4; B#, 1 ; C, 1 Not speciﬁed A, 2; B, 13;
C, 2$
B, 2; Y, 3 B, 1; C, 1;
Unknown, 3
Percentage of HHC correctly treated with CHP 95%* 25% 90% 95%* 37% 33%
Total number of HHC 8428 1506 802 9717 1510 1905
Number of HHC correctly treated 8007 381 722 9231 559 629
Number of HHC not or incorrect treated 421 1125 80 486 951 1276
Average household size 4.0 4.0 5.7 4 3.9 4.0
With correct CHP
Subsequent cases 0–13 days 0 0 0 2* 0 0
Subsequent cases 14–30 days 6 0 0 3* 0 0
Subsequent cases 31–365 days 1 1 n.a. 9* n.a. 1
SAR (per 1000 HHC) with CHP 0–13 days 0.0 0.0 0.0 0.2 0.0 0.0
SAR (per 1000 HHC) with CHP 14–30 days 0.7 0.0 0.0 0.3 0.0 0.0
SAR (per 1000 HHC) with CHP 31–365 days 0.9 2.6 n.a. 1.0 n.a. 1.6
Time interval primary-subsequent case 6, 18–28 days;
1, 92 days
35 days n.a. 3,<8 days;
5, 8–34 days;
3, 35–90 days;
6,>90 days·
n.a. 42 days
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polysaccharide) and by country. There would also be
high additional costs to the family and society of
death and disability.
The potential impact of routine vaccination of
household contacts on the attack rate among house-
hold contacts is shown in Danish surveillance data
[22]. In Denmark, vaccination of household contacts
has been recommended to the same group of persons
as for those who receive chemoprophylaxis when the
primary case is due to a vaccine-preventable sero-
group since 1992. Between 1980 and 1992, before the
introduction of this policy, seven serogroup C clusters
were reported in household settings, with eight sub-
sequent cases of which four occurred more than 15
days after hospitalization of the primary case. Be-
tween 1992 and 1996, after introduction of the vacci-
nation policy, ﬁve serogroup C clusters were recorded
in a household setting, all subsequent cases in these
clusters occurring within the ﬁrst 6 days after hospi-
talization of the primary case. The absence of late
cases suggests beneﬁt from vaccination.
The estimates of risk of meningococcal disease
among household contacts in the six studies were
consistent. All studies had limitations of data quality
from incomplete data or follow-up. However, most of
these limitations would have led to an underestimate
of the risk in household contacts, resulting in an
overestimate of the number needed to vaccinate to
prevent a case. First, only one of the six studies had a
follow-up period of 365 days, and only two detected
subsequent cases beyond a 6-week interval. The
longer the interval between the primary case and any
subsequent case, the more likely that the subsequent
case would be reported as a primary case. The in-
ability to link subsequent cases that occur more than
1 month after the primary case to the primary case,
results in an underestimation of the subsequent at-
tack rate. Second, the probable overestimate of theC
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Table 2. Sensitivity analysis – number needed to
vaccinate (NNV ) to prevent one case, or one death
Minimum Mean Maximum
SAR per 1000 HHC 1.6 1.1 0.7
Vaccine eﬃcacy (%) 95 90 85
Case-fatality rate (%) 10 7.5 5
NNV to prevent one
case
638 1033 1678
NNV to prevent one
death
6382 13777 33560
SAR, subsequent attack rate; HHC, household contact.
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proportion of household contacts given eﬀective
chemoprophylaxis in two studies would have led to
an underestimate of the attack rate in this group.
Third, the assumption of equal time distribution is
not likely to be correct. Cases in persons given eﬀec-
tive chemoprophylaxis occur later than in those not
or incorrectly treated. Fourth, the minimum period of
14 days assumed necessary for a vaccination strategy
to become eﬀective may be too long. Protective levels
of antibodies can be detected 5 days after vaccination
[23, 24] and, if there is more rapid diagnosis and
vaccine administration, the estimated 7-day interval
between diagnosis and vaccination [17] could be
reduced. Therefore, countries with rapid diagnostic
capacities and eﬃcient systems for vaccine adminis-
tration may be able to prevent more subsequent cases
among household contacts. Fifth, some contacts of
primary cases due to vaccine-preventable serogroups
may have actually been given meningococcal poly-
saccharide vaccines in addition to chemoprophylaxis ;
this information was not available in most studies.
One possible reason for overestimating risk would
be that some cases in clusters were clinically diag-
nosed, so that some may not have been true cases or
may have been due to a diﬀerent serogroup. However,
in all but one study the cases in household contacts
were microbiologically conﬁrmed and no clusters
were identiﬁed where the cases were due to diﬀerent
serogroups. To calculate the number of household
contacts of a primary case caused by a vaccine-
preventable serogroup needed to vaccinate to prevent
one secondary case we assumed a similar subsequent
attack rate for all serogroups including B. This as-
sumption is supported by data on clusters in edu-
cational settings [25]. Serogroup B clusters would not
be currently preventable by vaccination. Another
possibility is that the cases themselves may not have
been treated with antibiotics that eradicated carriage
[11] such that chemoprophylaxis of the household was
not optimal. Whatever drug regime is used it is clear
that chemoprophylaxis cannot be 100% eﬀective in
eradicating carriage in the household or in preventing
virulent strains from re-entering the family. Family
members among household contacts may also be at
increased risk due to genetic susceptibility.
Without the evidence of a randomized controlled
trial, the ﬁndings of this review support vaccination of
household contacts of meningococcal disease cases in
developed countries. We do not consider that the data
are strong enough to give point estimates of risk and
beneﬁt, but the true values of attack rate and number
needed to vaccinate are likely to lie within or below
the range of estimates given. The eﬀectiveness of giv-
ing serogroup A vaccines in a setting where antibiotics
are not used for household contacts has been shown
[24]. We believe that in developed countries, house-
hold contacts of a case should be given chemo-
prophylaxis and, if the primary case is caused by a
vaccine-preventable serogroup that contacts should
also receive an appropriate vaccine. Such a policy
would have a low impact on disease burden when the
incidence of disease due to such strains is low and as
most cases are sporadic [14, 26]. Conversely this
public health measure would also have a low cost and
our estimates suggest that it is cost eﬀective. Some
countries have recently seen a dramatic fall in inci-
dence following the introduction of meningococcal
serogroup C conjugate vaccines into childhood vac-
cination programmes [27]. Household contacts of
cases due to serogroup C and who have already re-
ceived C conjugate vaccine are expected to have long-
term protection. Moreover, although polysaccharide
vaccines are less eﬀective in young children, quadri-
valent conjugate vaccines are licensed in North
America [28], and may soon be available in Europe.
Therefore our recommendation should apply to
those contacts of cases caused by A, C, W135 and Y
strains who have not received an appropriate con-
jugate vaccine, and potentially in the future to con-
tacts of cases due to B serogroups when new vaccines
become available.
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